We determined the effect of cystoscopy (flexible and rigid), transrectal ultrasonography (with and without needle biopsy of the prostate) and transurethral resection of the prostate or bladder tumour on the serum prostate-specific antigen (PSA) concentration. Samples were taken from 60 men before and up to 14 days following these procedures.
INTRODUCTION
Prostate-specific antigen (PSA) is now recognized as the most useful tumour marker available for the detection and monitoring of prostate cancer. In the past, when acid phosphatase was used as a tumour marker for prostate cancer, documentation of elevation in the serum acid phosphatase concentration following digital rectal examination (DRE) raised concerns that PSA might be similarly affected. Most studies on the effect of DRE on serum PSA levels have shown only Correspondence: Tracy Dew. 340 minimal increases following examination, the vast majority of which would have been clinically insignificant. 1.2 Some studies have, however, shown that in patients with benign prostatic hyperplasia (BPH) whose initial serum PSA was in the 3·0-6·0 J.lg/L region increases of up to 004J.lg/L can be seen in the first 60 min following examination, but this was clinically significant in less than 2% of the population studied.' 5 The data on the effect of other investigative or operative procedures on serum PSA concentration are both limited and conflicting. Yuan et al. showed that DRE and transrectal ultrasound examination of the prostate (TRUS) had no significant effect on serum Influence of investigative and operative procedures on serum PSA 341 PSA immediately following the procedure, while needle biopsy of the prostate caused a marked elevation of serum PSA which persisted longer than the predicted half-life of PSA. 6 Similar results were reported by Deliveliotis et al. for cystoscopy, DRE and TRUS. 7 However, Stamey et al. reported rises in serum PSA in both rigid cystoscopy and TRUS. 8 We have monitored the serum PSA concentrations for 14 days in 60 patients undergoing cystoscopy (flexible or rigid), TRUS (with and without needle biopsy) and transurethral resection of the prostate (TURP) or bladder tumour (TURBT).
PATIENTS AND METHODS

Patients
Ten male patients (median age 66 years, range 61-79 years) undergoing flexible cystoscopy with an Olympus CY -2 cystoscope (Keymed Medical Industrial Ltd, Southend, Essex, UK; 14 Fr) for investigation of haematuria were enrolled in the study. Similarly, ten male patients (median age 66 years, range 55-76 years) undergoing bladder examination and biopsy with a 19 Fr Olympus rigid cystoscope were studied. Flexible cystoscopy was carried out using local anaesthesia, while general anaesthesia was used with the rigid cystoscope. Sterile water was used as the irrigant for both procedures.
Twenty men undergoing TRUS examination of the prostate using an Acuson model 128 x PIO ultrasound instrument (Diathermy Valley Lab, Ascot, Berkshire, UK) with a 7 MHz transducer were studied. Ten of these (median age 71 years, range 54-87 years) did not have needle biopsy, while ten (median age 70 years, range 54-79 years) had up to six biopsies taken with an automatic biopsy gun fitted with an 18 gauge needle. Four of the patients were found to have carcinoma on histological examination of the biopsies. Ten patients undergoing TURP for BPH (median age 73 years, range 61-84 years) and ten male patients undergoing TURBT (median age 65 years, range 48-88 years) were enrolled in the study. Both procedures were carried out using a 27 Fr Olympus continuous flow resectoscope with a 1·5% glycine solution as irrigant. None of the BPH patients had either foci of carcinoma or prostatic intraepithelial neoplasia (PIN) on histological examination. All patients undergoing TURBT had the procedure for primary tumour resection and none had had previous prostate surgery. The study was approved by the King's Healthcare Research Ethics Committee.
Samples and analytical methods Venous blood (7 ml) was taken into tubes without anticoagulant at the following time intervals and the serum separated and analysed for PSA the same day using the Immuno I analyser (Bayer Diagnostics, Newbury, Berks):
TO pre-procedure Tl 1 day post-procedure T2 2 days post-procedure T ABLE I. Serum prostate-specific antigen (PSA) median (range ) before and after cystoscopy, transrectal ultrasound (TRUS). transurethral resection ofprostate (TURP) and transurethral resection ofbladder tumour (TURBT)
Pre-I day post-2 days post-3 days post-7 days post-14 days postprocedure procedure procedure procedure procedure procedure Increase % Increase T3 3 days post-procedure T4 7 days post-procedure T5 14 days post-procedure The PSA method on the Irnrnuno I is an immunoenzymetric assay. Between-batch imprecision was 4·2% CV at 0·38jlg/L, 2·5% CV at 6·9 jlg/L and 2·7% at 24·8 jlg/L (n = 20).
Statistical analysis
Wilcoxon matched-pairs signed ranks test with correction for ties was used to determine if changes in PSA following investigative or operative procedures were statistically significant. Analysis was carried out using Astute for Excel (Leeds University, UK).
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RESULTS
The median serum PSA concentration for each patient group before and after the various procedures are given in Table 1 . The serum PSA results for the individual patients and the median PSA concentration before and after cystoscopy are shown in Fig. I . There was no significant increase in serum PSA following flexible cystoscopy at any of the time points post-procedure (P> 0'05). There was a small increase in serum PSA I day following rigid cystoscopy [median increase 0·15 jlgjL (P = 0,04)], which returned to normal after 3 days. One patient with a pre-cystoscopy PSA of 3·2 jlg/L had a marked increase in PSA at 2 days, Influence ofinvestigative and operative procedures on serum PSA 343 to 14J1g/L, which had not returned to normal at 14 days. Further investigation of this patient revealed he had co-existing BPH.
The serum PSA results for the individual patients before and after TRUS with and without needle biopsy of the prostate are shown in Fig. 2 . There was a slight increase in serum PSA concentrations at day I following TRUS alone [median increase 0·3 J1g/L (P=O'OI)] which returned to normal after 2 days. TRUS with needle biopsy of the prostate produced a significant increase in serum PSA 1 day post-procedure [median increase of PSA was 6·0 J1g/L (P=Q'004)], which persisted for 7-14 days in most patients.
The serum PSA concentrations before and after TURP and TURBT for the individual patients are shown in Fig. 3 . TURP produced a rise in the serum PSA concentration (P < 0·00 I), which returned to the pre-procedure levels after 14 days. The median increase in serum PSA concentration was 13J1g/L, but in one patient the rise was 62 J1g/L.TURBT resulted in a small rise in serum PSA concentrations I day post-procedure in the majority of patients (P = 0'005), which again took 7-14 days to return to pre-procedure levels. The median increase in serum PSA was 2·6 J1g/Lbut in three patients a normal serum PSA pre-procedure became abnormal for 2-7 days after TURBT.
DISCUSSION
The serum concentration of PSA is a function of its production by prostate epithelial cells, of Ann Clin Biochem 1999: 36 leakage into the circulation and of clearance. While normal practice is to take blood samples for measurement of PSA prior to any procedure which might disturb the prostate, there are occasions where this is not always possible, Although there is reasonable agreement in the literature that ORE may produce small increases in serum PSA, these are only rarely of clinical significance. There is, however, much less of a consensus regarding the impact of other investigative procedures on serum PSA concentrations. This study looked at the effect of cystoscopy (flexible and rigid), transrectal ultrasonography (with and without needle biopsy of the prostate) and transurethral resection of the prostate or bladder tumours on the serum prostate-specific antigen concentration. The number of subjects in each procedural group was relatively small (n= 10), but this was sufficient to detect changes in PSA that could be deemed 'clinically significant', e.g., greater than 1·5 j1gjL. What value of PSA increase (due to operative or investigative invasion) is deemed 'clinically significant' obviously varies with the pre-operative PSA value, i.e., at a pre-operative serum PSA of3'5j1gjL a rise ofO'8j1gjL may well be significant but this degree of increase would be insignificant at a starting PSA of 20 j1gjL. We found that flexible cystoscopy did not produce a significant change in serum PSA, the median increase being 0·1 j1gjL. This is in agreement with Oesterling et al", who also found a median increase of 0·1 j1gjL. Deliveliotis et al.' also found that flexible cystoscopy did not result in any significant increase in serum PSA 24 h post-procedure, although they did observe a rise in PSA in the first 5 min after cystoscopy in 10'Yo of patients. In contrast, rigid cystoscopy with bladder biopsy resulted in a small rise in serum PSA which was just statistically significant and which normalized after 7 days. One other group has reported similar results with increases in PSA of approximately 50%, returning to normal after 15 days.!" A further report of increases in serum PSA after cystoscopy does not state whether a flexible or rigid cystoscope was used.'
In patients undergoing TRUS without prostatic biopsy we observed a slight elevation of the serum PSA concentration after 1 day (median increase 0·3 j1gjL), which was statistically significant but would not have been clinically significant in any patient. The PSA results had normalized by 2 days after TRUS. In the majority of studies of the effect of ultrasonography on serum PSA concentrations, needle biopsy of the prostate was carried out. Yuan et al. fi studied 27 men who had TRUS without biopsy and found PSA to be falsely increased in only three patients. There is general agreement that TRUS without needle biopsy docs not result in significant rises in PSA in most patients.v'"!'
In patients in whom an ultrasound-guided needle biopsy was carried out we found a median increase in PSA concentration of 6·0 j1gjL, which is similar to the 7·9 j1gjL rise reported by Oesterling et al? In a recent study Ornstein et al. demonstrated that needle biopsy produced a rise in both total and free PSA in serum. I I The percentage of free PSA was dramatically increased I h after biopsy (62% vs 21·5% prior to biopsy) and had returned to normal in 90% of men by 24 h after the procedure. Within the TRUS and biopsy group four patients had carcinoma of the prostate and six had BPH. It is feasible that the larger prostate gland volume typically found in BPH (compared with that in prostate cancer) could lead to an altered pattern of PSA release. Examination of the individual results did not indicate a particular difference in PSA release following biopsy, but larger numbers of patients in each group would be necessary to confirm this.
Transrectal resection of the prostate caused considerable increases in serum PSA, which slowly returned to normal over the next 14 days. We have recently shown that free PSA is released following TURP and complexation with the protease inhibitors occurs over 24 h. 12 This is in keeping with the findings of Ornstein et al," for needle biopsy and presumably reflects the leakage of prostatic contents into the circulation following disruption of the prostatic capsule. Oesterling et al.' recommended that samples should not be taken for serum PSA estimation until 6 weeks after disruption of the prostate capsule by biopsy or TURP. This is probably on the conservative side as our data from this study and the TURP study'? suggest that all patients achieve their pre-operative serum PSA level after 3 weeks. The small but significant rise in PSA we observed following TURBT has not previously been reported and suggests that some trauma to the prostate occurs during the procedure.
In conclusion, flexible cystoscopy and TRUS without biopsy do not cause a significant increase in serum PSA, and samples can safely be taken 24-48 h after these procedures. Small rises in serum PSA are seen following rigid cystoscopy and TURBT and it would be prudent to wait 7-14 days before taking blood for estimation of PSA. Needle biopsy of the prostate or TURP causes a significant elevation of serum PSA and values do not return to baseline for 14 days. The observations by Ornstein et al." and our group'-that free PSA is preferentially released after disruption of the prostatic capsule suggest that this may also apply to the smaller increases seen after rigid cystoscopy or TURBT. If the free:bound PSA ratio is used to attempt to improve diagnostic discrimination between BPH and carcinoma of the prostate, this may be unreliable for 7--14 days following any trauma to the prostate. Further studies are needed to ascertain whether DRE, catheterization or acute retention could alter this free:bound ratio.
